Interactions of human organic anion transporters with aristolochic acids

Journal of Pharmacological Sciences

Volumn 113, Issue 2, 2010, Pages 192-196

  Babu, Ellappan ^a   Takeda, Michio ^a   Nishida, Ritsuo ^b   Noshiro Kofuji, Rie ^a   Yoshida, Masaaki ^c   Ueda, Shiro ^d   Fukutomi, Toshiyuki ^a   Anzai, Naohiko ^a   Endou, Hitoshi ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c Kotarou Kanppo Co Ltd   (Japan)

^d CHIBA UNIVERSITY   (Japan)

Author keywords

Aristolochic acid; Aristolochic acid nephropathy; Organic anion transporter

Indexed keywords

ANION; ARISTOLOCHIC ACID; ORGANIC ANION TRANSPORTER; PROBENECID; ARISTOLOCHIC ACID I; HERBACEOUS AGENT;

ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; DRUG INDUCED DISEASE; DRUG MECHANISM; HUMAN; NEPHROTOXICITY; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL SURVIVAL; DRUG EFFECTS; DRUG INTERACTION; METABOLISM; TOXICITY;

ANIMALS; ANIONS; ARISTOLOCHIC ACIDS; CELL SURVIVAL; CELLS, CULTURED; DRUG INTERACTIONS; DRUGS, CHINESE HERBAL; ORGANIC ANION TRANSPORTERS; PROBENECID;

EID: 77953814077     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09339SC     Document Type: Article

References (15)

1. Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, et al. Rapidly progressive interstitial fibrosis in young woman: association with slimming regimen including Chinese herbs. Lancet. 1993;341:387-391.
2. Tanaka A, Nishida R, Maeda K, Sugawara A, Kuwahara H. Chinese herb nephropathy in Japan presents adult-onset Fanconi syndrome: could different components of aristolochic acids cause a different type of Chinese herb nephropathy? Clin Nephrol. 2000;53:301-306.
3. Vanhaelen M, Vanhaelen-Fastre R, But P, Vanherweghem JL. Identification of aristolochic acid in Chinese herb. Lancet. 1994;343:174.
4. Cosyns JP, Goebbels RM, Liberton V, Schmeiser HH, Bieler CA, Bernard AM. Chinese herbs nephropathy-associated slimming regimen induces tumors in the forestomach but no interstitial nephropathy in rats. Arch Toxicol. 1998;72:738-743.
5. Jackson L, Kofman S, Weiss A, Brodovosky H. Aristolochic acid (NSC-50413): phase I clinical study. Cancer Chemother Report. 1964;42:35-37.
6. Mengs U, Lang W, Poch JA. The carcinogenic action of aristolochic acid in rats. Arch Toxicol. 1982;61:107-119.
7. Lebeau C, Arlt VM, Schmeiser HH, Boom A, Verroust PJ, Devuyst O, et al. Aristolochic acid impedes endocytosis and induces DNA adducts in proximal tubule cells. Kidney Int. 2001;60:1332-1342.
8. Lebeau C, Debelle FD, Arlt VM, Pozdzik A, De Prez EG, Phillips DH, et al. Early proximal tubule injury in experimental aristolochic acid nephropathy: functional and histological studies. Nephrol Dial Transplant. 2005;20:2321-2332.
9. Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, et al. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci U S A. 2007;104:12129-12134.
10. Anzai N, Endou H. Drug transport in the kidney. In: You G, Morris ME, editors. Drug transporters molecular characterization and role in drug disposition. New Jersey: John Wiley & Sons, Inc.; 2007. p. 463-494.
11. Tachampa K, Takeda M, Khamdang S, Noshiro-Kofuji R, Tsuda M, Jariyawat S, et al. Interactions of organic anion transporters and organic cation transporters with mycotoxins. J Pharmacol Sci. 2008;106:435-443.
12. 13C NMR spectroscopy of aristolochic acids and aristololactams. Magn Reson Chem. 1989;27:460-469.
13. Babu E, Takeda M, Narikawa S, Kobayashi Y, Enomoto A, Tojo A, et al. Role of human organic anion transporter 4 in the transport of ochratoxin A. Biochim Biophys Acta. 2002;1590:64-75.
14. Shibutani S, Dong H, Suzuki N, Ueda S, Miller F, Grollman AP. Selective toxicity of aristolochic acids I and II. Drug Metab Dispos. 2007;35:1217-1222.
15. Liu MC, Maruyama S, Mizuno M, Morita Y, Yuzawa Y, Hanaki S, et al. The nephrotoxicity of Aristolochic manshuriensis in rats is attributable to its aristolochic acids. Clin Exp Nephrol. 2003;7:186-194.